Last reviewed · How we verify
NCT04847817: AIDCO
Important Data on COVID-19 Profile in Africa
trial in Coronavirus Infection in 574 participants. Completed in 1 March 2022.
31 December 2021
Quick facts
| Lead sponsor | Centre de Recherche Médicale de Lambaréné |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 574 |
| Start date | 1 August 2020 |
| Primary completion | 31 December 2021 |
| Estimated completion | 1 March 2022 |
| Sites | 2 locations across Gabon |
Conditions studied
- Coronavirus Infection — all drugs for Coronavirus Infection →
- Africa — all drugs for Africa →
Sponsor
Centre de Recherche Médicale de Lambaréné — full company profile →
Who can join
Eligibility, any sex, with Coronavirus Infection or Africa. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to Understand the natural history of Coronavirus 2019 (COVID-19) infection to better define the period of infectiousness and transmissibility and to establish biobanks of COVID-19 blood and mucosal samples.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04847817
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronavirus Infection
Currently open trials in the same condition.
- NCT04885504 — Post COVID-19 Biorepository · recruiting
- NCT04445454 — Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection · Phase 1, PHASE2 · recruiting
- NCT04510025 — Capturing MultiORgan Effects of COVID-19 · recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
Other Centre de Recherche Médicale de Lambaréné trials
Trials by the same sponsor.
- NCT07017803 — Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region · not yet recruiting
- NCT05905432 — Pan-Malaria Transmission-Blocking Vaccine AnAPN1 · Phase 1 · completed
- NCT05929157 — A Crossover Bioavailability Clinical Trial of Parenteral Pyronaridine and Artesunate · Phase 1, PHASE2 · unknown
- NCT05130398 — Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon · Phase 1, PHASE2 · completed
- NCT04505046 — Validation of INSPiRED Innovative Smart Diagnostic Devices for the Detection of Parasites Infections. · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04847817 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre de Recherche Médicale de Lambaréné
- Last refreshed: 19 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04847817.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing